DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

EXenatide Study of Cardiovascular Event Lowering



Trial Management

Executive Committee (EC)

The Executive Committee is responsible for the overall management, oversight and reporting of the trial.

Members    
Rury Holman UK Endocrinologist (Joint Chair)
Adrian Hernandez US Cardiologist (Joint Chair)
     
John Buse US Endocrinologist
Juliana Chan China Endocrinologist
Aldo Maggioni Italy Cardiologist
Steve Marso US Cardiologist
Neil Poulter UK Cardiologist
Ambady Ramachandran India Endocrinologist
Bernie Zinman Canada Endocrinologist

Data Safety Monitoring Board (DSMB)

The DSMB safeguards the interests of trial participants, monitors the main outcome measures including safety and efficacy, and monitors the overall conduct of the trial.

Members    
Jean Rouleau

Canada Cardiologist (Chair)
Fred Gorelick US Gastroenterologist
John McMurray UK Cardiologist
Stuart Pocock UK Statistician
Matt Riddle US Endocrinologist
Robert Gagel US Endocrinologist (specialising in thyroid cancer)

Operations Committee (OC)

The Operations Committee is comprised of country lead investigators. The primary role of the OC is to serve as the interface between the Executive Committee and the trial sites and to monitor and supervise the progress of the trial at a country level.

Study Sponsor

Amylin Pharmaceuticals, LLC (a wholly owned subsidiary of AstraZeneca).